Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Brain Neoplasms 22Carcinoma, Non-Small-Cell Lung 17Pancreatic Neoplasms 11Neoplasm Metastasis 11Prostatic Neoplasms 9Melanoma 9Lung Neoplasms 9Glioblastoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Squamous Cell Carcinoma of Head and Neck 6Glioma 6Carcinoma, Renal Cell 6Neoplasms 5Colorectal Neoplasms 5Head and Neck Neoplasms 4Uveal Melanoma 3Oligodendroglioma 3Liver Neoplasms 3Gliosarcoma 3Astrocytoma 3Adenocarcinoma 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2

Interventions

Sorafenib 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1fisogatinib 1ficlatuzumab 1belinostat 1bavituximab 1avelumab 1Trabectedin 1Radiotherapy 1Radiosurgery 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Immunotherapy 1Dexamethasone 1Carboplatin 1Azacitidine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liver Diseases × Radiosurgery × Clear all
NCT02989870 2020-06-05

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡